Marksans Pharma has entered into a definitive agreement to acquire 100% of the share capital of Netherlands-based QliniQ B.V. for a cash consideration of €7.5m. Announced on June 01, 2026, the acquisition is a strategic step to expand Marksans' presence across regulated European markets by establishing direct, owned market-access capabilities in the European Union. The transaction is expected to be completed by June 15, 2026, and is not a related party transaction.

Strategic Rationale

QliniQ B.V. operates a differentiated portfolio of niche pharmaceuticals and medical devices, with established positions across women's health, dermatology, respiratory care, and other specialty categories. The company provides established sales, marketing, and distribution capabilities in the Netherlands, supported by EU GDP-compliant warehousing and regulatory infrastructure. QliniQ maintains long-standing relationships with wholesalers, pharmacies, hospitals, and insurer-led tender channels, which Marksans aims to leverage for the commercialisation of its existing and future product portfolio. The acquisition will enable Marksans to utilise QliniQ's front-end sales and marketing infrastructure to market products manufactured in India, the UK, and the USA.

Financial Performance of QliniQ B.V.

The target entity has delivered strong profitable growth, reporting a revenue CAGR of approximately 41% between FY2023 and FY2025, while maintaining a debt-free balance sheet. The following table presents QliniQ's key audited financials for the financial year ended December 31, 2025:

Acquisition Details

The acquisition will be funded through cash consideration, with no governmental or regulatory approvals required for the transaction. The Board of Directors of Marksans Pharma approved the strategic move to bolster the company's footprint in European markets. QliniQ's portfolio spans women's health, dermatology, respiratory/ENT, endocrinology, and gastroenterology, with several first-to-market positions.

Albert de Bruin and Raymond Lansink, Board members and Shareholders of QliniQ B.V., expressed confidence in the merger, citing Marksans' track record in product development and commitment to quality. Mark Saldanha, Chairman and Managing Director of Marksans Pharma, highlighted that the acquisition provides direct access to the Netherlands market and enhances the ability to commercialise products across regulated European markets.

Marksans Pharma has charted an aggressive expansion strategy, anchored by a robust product pipeline, geographic diversification, and disciplined financial targets. The company plans to launch approximately 50 products in the US by 2026-27, with additional product launches expected in other markets, as it works toward doubling its revenue over the next 3-5 years.

US Pipeline and R&D Commitments

The company's near-term growth strategy is heavily focused on the US market, with around 50 product launches planned by 2026-27. R&D spending is expected to be maintained at 3% of total revenue, reflecting a steady commitment to innovation without significant escalation in expenditure. The company noted that approval for products generally takes about a year, meaning results from current investments may begin to materialize by late FY27 or early FY28.

Geographic Expansion: Europe, Canada, and Australia

Marksans Pharma is actively pursuing revenue contributions from multiple geographies beyond the US. Key timelines and targets for international markets are outlined below:

The company's Australia ambitions are particularly notable, with a target of $100 million in revenue within a three-year horizon, underscoring its focus on building a meaningful presence in the market.

M&A Strategy and Due Diligence

Marksans Pharma anticipates M&A developments in 2027 and is currently conducting due diligence on one of two potential acquisition targets. The company has not disclosed further details on the targets, but the active due diligence process signals a structured approach to inorganic growth as part of its broader expansion plans.

Financial Targets and Margin Outlook

The company has set clear financial milestones for the medium term. The following table summarizes the key financial guidance provided:

For FY27, EBITDA margins are expected to remain in the range of 20% to 21%, while revenue growth is anticipated between 15% and 20%. The longer-term ambition to double revenue over the next 3-5 years reflects the company's confidence in its pipeline and geographic expansion strategy.

Key Highlights

• Approximately 50 product launches planned in the US by 2026-27, with more products expected in other markets
• R&D spending to be maintained at 3% of total revenue
• Europe revenue expected in the second half of FY27; Canada contributions anticipated by end of FY27
• Australia revenue target of $100 million within three years
• M&A developments anticipated in 2027, with due diligence underway on one of two potential targets
• INR 4,000 crores revenue target set for FY28
• Revenue growth guidance of 15% to 20% for FY27 with EBITDA margins of 20% to 21%